

Transplantation

By

K.T. Brunner · C.E. Calkins · J.-C. Cerottini · C.C. Congdon · E.L. Cooper
H. Cottier · D.A.L. Davies · F. Eitel · J. Hagmann · E.S. Henderson
M. Hess · M.W. Hess · E.N. Hinzpeter · H.P. Hobik · T. Hraba · M. Jäger
P.H.K. Jap · M. Jeannet · C.R. Jerusalem · G.R.F. Krueger · H.U. Keller
Z.J. Lucas · G.O.H. Naumann · R. Pichlmayr · L. Schweiberer
M. Segall · R. Storb · O. Stutman · C.J. Wirth · K. Wonigeit

Edited by

Johann Wilhelm Masshoff

With 233 Figures



Springer-Verlag Berlin Heidelberg New York 1977

Contents

The Main Histocompatibility System in Man. M. JEANNET. With 2 Tables	1
A. Introduction	1
B. Historical Background	1
C. Methodology and Serological Considerations	3
I. Leukoagglutination	3
II. Lymphocyte Cytotoxicity	4
III. Platelet Complement Fixation	4
IV. Serum Sources	4
1. Polytransfused Patients	5
2. Pregnancy	5
3. Immunization of Human Volunteers	5
4. After Organ Transplantation	6
5. "Natural" Lymphocytotoxins	6
6. Immunization of Animals	6
D. Genetics of the HL-A System	7
E. Heterogeneity and Cross-Reactivity of HL-A Antigens	9
F. HL-A, Mixed Lymphocyte Culture (MLC), Cell-Mediated Lympholysis (CML), and Cellular Immunity	10
G. HL-A System and Clinical Transplantation	12
I. Skin Graft Survival	12
II. Kidney Transplantation	12
III. Variability in the Host Immune Response	15
IV. Donor Selection for Kidney Transplantation	17
V. Bone Marrow Transplantation	18
H. HL-A System and Human Diseases	20
I. HL-A and Hematologic Malignant Diseases	20
II. HL-A and Cancer (other than Lymphomas)	22
III. HL-A and Immunopathic Diseases	22
IV. HL-A and Infectious Diseases	23
V. HL-A and Rheumatoid Diseases	24
VI. HL-A System and Various other Diseases	25
I. HL-A System and Blood Transfusion	25
J. HL-A System and Disputed Paternity Cases	26
K. Conclusions	27
References	27
 Gene Products of the Major Histocompatibility Complex: Biology and Chemistry. D.A.L. DAVIES and M. HESS. With 19 Figures and 8 Tables	 39
1. Introduction	39

2. The MHC in Man and Animals	41
2.1 Similarities	41
2.2 Differences	42
3. Biology of Human MHC Products	43
3.1 HL A Antigens	43
3.2 β 2-Microglobulin (β 2m)	45
3.3 Ir-Region in Man	48
3.4 Association of HL A with Disease	50
4. Additional Information from Animal Studies	52
4.1 Genetics of the H-2 Complex	52
4.2 I-Region Traits and Functions	62
4.3 Donor Specific Prolongation of Transplant Survival	64
5. Chemistry of Human and Mouse MHC Gene Products	68
5.1 Homology	68
5.2 Membranes and Models	68
5.3 Methods	70
5.4 Biochemistry of HL A/H-2 Antigens	76
5.5 β 2-Microglobulin	84
5.6 Immune Response Region Associated Antigens (Ia)	86
6. Concluding Remarks	91
References	92

Lymphocyte—Defined Components of the Major Histocompatibility Complex. MIRIAM

SEGALL. With 7 Figures and 10 Tables	105
A. Introduction. General Principles of MLC	105
B. Technical and Statistical Aspects of Human MLC	106
I. Macro- and Micro-Methods	106
II. Determination of Non-Stimulation	107
1. Controls	107
2. Statistical Analysis	108
3. Quantitation of MLC Results	110
C. Mouse MLC Techniques	114
D. Genetics of MLC in Humans	115
I. Basic Principles	115
II. Correlation of MLC Non-Stimulation in Siblings with Inheritance of the Same HL-A Haplotype	118
III. Exceptional Cases of Stimulation and Non-Stimulation	119
IV. Association of Stimulation with Four-Locus Region	121
V. Minor loci	121
VI. MLC and HL-A Typing in Unrelateds	122
E. Genetics of MLC in the Mouse	126
F. MLC Typing	127
I. Principle of Typing—Use of Homozygous Cells	127
II. Problems in Defining a "Typing" Response	129
G. Cell-Mediated Lympholysis (CML) Reaction	130
I. CML in the Human	130
II. CML in the Mouse	131
III. Relation of CML and MLC	132
H. Correlations of MLC with Grafting	132
I. Conclusion	134
Appendix I. Statistical Definitions	134
Appendix II. Definition of Genetic Terms	135
Addendum	136
References	136

Phylogenetic Aspects of Transplantation. EDWIN L. COOPER. With 4 Figures	139
A. Introduction	139
B. Transplantation Reactions in Invertebrates Other than Annelids and Echinoderms	140
1. Organelle Transplantation in Protozoans (Sarcodina, Ciliata)	140
2. Metazoans—Specificity of Reaggregation in Porifera	140
3. Incompatibility in Cnidaria (Hydrozoa, Anthozoa)	141
4. Platyhelminthes and Sipunculida	141
5. Equivocal Incompatibilities in Mollusca (Pelecypoda, Gastropoda, Cephalopoda)	142
6. Arthropoda	143
7. Genetic Control in Urochordata	143
8. Summary of Quasi Immunorecognition	144
C. Transplantation Reactions in Invertebrates that Reveal Primordial Cell-Mediated Immunity	144
I. Short-term Immunologic Memory	144
II. Cell and Tissue Responses that Indicate Self Recognition in Echinoderms	145
III. Transplantation in Asteroidea	145
IV. Short-term Memory	145
V. The Earthworm Model	146
1. First- and Second-Set Allograft Rejection in <i>Lumbricus terrestris</i> and <i>Eisenia foetida</i>	147
2. Rejection of First- and Second-Set Xenografts Exchanged between <i>Lumbricus</i> and <i>Eisenia</i>	147
3. Specificity and Anamnesis	148
4. The Cellular Response	149
5. The Role of Temperature in Earthworm Tissue Graft Rejection	151
6. Summary	151
D. Transplantation Immunity in Fishes	151
I. Introduction	151
II. The Hagfish	151
III. The Lamprey	152
IV. Cartilaginous Fishes	152
V. Bony Fishes (Holosteans; Teleosts)	152
E. Transplantation Immunity in Amphibians	153
I. Adult Apodans	153
1. Introduction	153
2. General Description of Autografts and Allografts	153
3. Histopathology	154
II. Adult Urodeles	155
1. The Latent Phase	155
2. The Rejection Phase	156
3. The Chronic Rejection Response to Xenografts	156
4. Role of the Thymus in Graft Rejection	156
5. Histologic Differences in Skin	157
6. Suppression of Transplantation Immunity	157
III. Anurans	159
1. Larvae	159
2. Bone Marrow Restoration of Transplantation Immunity in Adult Leopard Frogs	161
F. Transplantation Immunity in Reptiles	162
I. Introduction	162
II. The Chronic Response in Turtles	162
III. The Importance of Temperature in Turtles	162
IV. The Mexican Iguana	163
V. The Garter Snake	163
References	164

Ontogenetic Aspects. OSIAS STUTMAN and CATHERINE E. CALKINS. With 3 Figures and 3 Tables	169
A. Introduction	169
B. Ontogeny of Lymphoid Structures	170
C. Ontogeny of Transplantation Immunity	179
D. Ontogeny of Thymus-Dependent Functions	181
E. Concluding Remarks	186
References	187
 Humoral and Cell-Mediated Mechanisms of Allograft Rejection. K. THEODOR BRUNNER and JEAN-CHARLES CEROTTINI	195
A. Introduction	195
B. Assay Methods of Cell-Mediated Cytotoxicity (CMC)	198
C. Cytotoxicity Mediated by Specifically Sensitized T-Cells	200
D. In Vivo Formation of Cytotoxic T Lymphocytes	201
E. In Vitro Formation of Cytotoxic T Lymphocytes	202
F. Mechanism of T-Cell Cytotoxicity	203
G. Specificity of Target Cell Destruction by Cytotoxic T Lymphocytes	204
H. Antibody-Dependent Cytotoxicity Mediated by Normal Lymphoid Cells	205
I. Cytotoxicity Mediated by Macrophages	207
K. Relevance of CMC to Allograft Rejection	209
L. The Role of Antibody in Allograft Rejection	210
References	212
 Cell Systems Participating in Graft Rejections. J. HAGMANN, M.W. HESS, H.U. KELLER and H. COTTIER	217
A. Introduction	217
B. Lymphocytes	217
I. Development of the Immune System and Lymphocyte Subclasses	217
1. Early Ontogenesis of Lymphoid Organs and Cells	217
2. Postnatal Development of the Lymphocytic Systems	218
3. The Central Role of the Thymus	219
II. Peripheral Lymphocytes	223
1. Lymphocyte Subclasses	223
a) T Cells	223
b) B-cells	226
c) Null Cells	229
2. The Functions of Peripheral Lymphocytes	229
a) Helper and Suppressor Activity	229
b) Cell-Mediated Cytotoxicity	230
c) Mixed Lymphocyte Cultures	232
d) Graft-Versus-Host Reaction (GVHR)	233
C. Macrophages	234
D. Neutrophilic Granulocytes	235
E. Other Cells and Structures	235
References	235
 General Tolerance Phenomena. T. HRABA	247
A. Introduction	247
B. Tolerance Phenomena and Other Specific Inhibitions of Immune Reactions	249
1. Inhibition States Classified as Immunologic Tolerance	250

1. The Sulzberger-Chase Phenomenon	250
2. Immunologic Paralysis	250
3. Tolerance to Heterologous Serum Proteins	251
4. Tolerance to Other Antigens	253
II. Other Antigen-Induced States of Specific Inhibition of the Immune Response	253
1. Immunologic Enhancement	253
2. Immune Deviation	254
C. Mechanisms of Immunologic Tolerance	254
I. The Relation of Antibody-induced Suppression to Immunologic Tolerance	254
II. Cellular Processes in Immunologic Tolerance	256
III. Suppressor Cells	258
IV. Transplantation Tolerance	260
V. Mechanism of Unresponsiveness to Self Components	262
D. Conclusions	264
References	265

Transplantation of Cells: Experimental and Clinical Observations. GERHARD R.F. KRUEGER. With 44 Figures and 3 Tables	275
A. Introduction	275
B. Historical Notes	276
C. Cell Types Used for Transplantation and Indications for the Respective Procedure	278
I. Experimental Transplantation	278
II. Human Transplantation	284
1. Indications for Transplantation of Blood and its Components	284
2. Indications for Transplantation of Bone Marrow	284
D. Techniques of Cell Transplantation	287
I. Details of Patient Selection	287
1. Selection of the Host	288
2. Selection of the Donor	288
II. Preevaluation and Pretreatment of Host and Donor	288
1. Pretreatment of the Donor	288
2. Pretreatment of the Recipient	289
III. Procurement of Bone Marrow Cells	294
IV. Cell Grafting	296
V. Cells other than Bone Marrow Cells used for Transplantation in Man	296
VI. Posttransplant Clinical Investigation of Bone Marrow Recipient	297
E. Demonstration and Localization of Engrafted Cells	300
F. Graft-Host Interactions	311
I. Microenvironmental Influences	311
II. Graft Rejection	312
III. Graft-Versus-Host Reaction (GVHR)	318
IV. Therapeutic Intervention of Postengraftment Disease	320
G. Conclusions	321
References	322

Skin Grafts in Animals and Man. ZOLTAN J. LUCAS. With 4 Figures and 3 Tables	329
A. Introduction	329
B. Operational Definition of Transplant Antigens	330
C. Morphologic Changes Occurring in Skin Allografts	332
I. Sequential Changes in Gross and Microscopic Appearance	333
II. Characterization and Quantitation of the Infiltrating Cells	335
III. Comparison of Morphologic Events in the Homograft Reaction and in other Hypersensitivity Reactions	335

D. The Immune Responses Induced by Skin Grafting	339
I. Afferent Phase—Antigen Recognition	341
II. Central Phase—Clonal Proliferation, Yielding both Memory and Differentiated Effector Cells	344
III. Effector Phase—the Expression of Immunity	344
1. Specific Immune Cytotoxic Mechanisms	344
2. Recruitment of Nonsensitized Effector Cells by Lymphokines Secreted by Sensitized T-Cells	346
3. Local Activation of the Host's General Inflammatory Response	347
4. Correlation of Immunologic and Pathophysiologic Events with Clinical Skin Graft Rejection Syndromes	348
IV. Autoregulatory Phase	349
1. Complete or Partial Tolerance	350
a) Conditions Affecting Induction, Maintenance, and Reversal of Immunologic Tolerance	350
b) The Absence of Reactive Cells or the Presence of Nonreactive Cells	351
c) The Presence of Immunologically Active Lymphocytes Blocked by Serum Factors	351
d) Other Alternatives: Suppressive or Regulatory Events Mediated by Lymphocytes on Immune Reactions	352
2. Immunologic Enhancement	352
a) General Features of Graft Survival	352
b) Relationship Between Organ Vascularity and Immunologic Enhancement	353
References	354

Transplantation of Connective Tissue. M. JÄGER and C.J. WIRTH. With 16 Figures	359
A. Introduction	359
B. General Section	360
I. Anatomic Structure of Connective-Tissue Types as it Affects Suitability for Transplantation	360
II. Viability and Nonviability: Denaturation of the Graft as it Affects Primary Healing and Restructuring	361
III. Biological and Mechanical Merits of Auto-, Homo-, and Heterologous Transplants	362
IV. Changes with Age in Connective Tissue as they Affect Transplantation	365
V. Immune Reactions in the Transplantation of Living and Preserved Connective Tissue	367
VI. Preservation	368
VII. Healing	377
C. Specific Section	380
I. Tendon	380
II. Cutis	382
III. Fascia	384
IV. Dura	385
D. Future Prospects	392
References	393

Transplantation of the Cornea in Man and Animal. E.N. HINZPETER and G.O.H. NAUMANN. With 11 Figures and 9 Tables	403
I. Introduction and Historical Background	403
II. Basic Principles of Keratoplasty	404

A. Terminology	404
B. Indications for Keratoplasty	405
C. Criteria for Donor Material and Storage	407
1. General	407
2. Donor-Cornea Evaluation (Laboratory and Clinical)	408
3. Storage	409
D. Surgical Techniques in Keratoplasty	411
E. Factors Determining Prognosis of Keratoplasty	412
1. Quality of the Donor-Cornea	412
2. State of the Recipient Cornea	413
3. Other Ocular Disease	414
4. Quality of Surgery	415
F. Healing of the Corneal Wound in Keratoplasty	415
G. Fate of Donor Cells in Keratoplasty	416
III. Unsuccessful Keratoplasty	417
A. Nonimmunologic Factors for Graft Failure	418
B. Immunologic Reasons for Graft Failure	421
IV. Experimental Keratoplasty and Heterografting	431
References	432

General Pathology of the Transplantation Reaction in Experimental and Clinical Organ

Grafts. CHRISTOPH R. JERUSALEM and PAUL H.K. JAP. With 61 Figures	439
A. The Many Facets of the Transplantation Reaction	439
I. Introduction	439
II. Terminology	440
1. Donor-Recipient Relationship	440
2. Chronologies of Rejection	441
III. Elements of the Transplantation Reaction	442
1. Dichotomy of the Immune Response	442
2. T-Helper Cell Mechanisms	446
3. Effector Mechanisms of Cell-Mediated Cytotoxicity	447
a) Autonomy of T-Lymphocyte Cytotoxicity	448
b) Mediators of the Cellular Immune Reaction	449
c) Cell-Mediated Cytotoxicity Independent of Thymus	451
IV. Humoral Factors Involved in Graft Rejection	456
B. Effector Cells and the Target Cell Injury	457
I. Morphology of Infiltrating "Lymphoid Cells"	457
1. Small Lymphocytes	458
2. Medium-Sized Lymphocytes	458
3. Atypical Lymphocytes	458
4. Large Lymphocytes	459
5. Transformed Lymphocytes	459
6. Lymphoid Killer Cells	460
7. Monocytes	460
8. Macrophages	461
II. Morphology of the Cell-Mediated Target Cell Destruction <i>in vitro</i>	464
1. Membrane Contact	464
2. Morphology of Cell-Mediated Target Cell Lysis	465
3. Morphology of Antibody-Dependent Cell-Mediated Cytotoxicity	466
4. Other Mechanisms of Cell-Mediated Target Cell Destruction	467
III. Features of Antibody-Mediated Injury	467
1. Morphology of the Complement-Dependent Immune Cytolysis	468
2. Relationship Between Immune Complexes and Clotting	468
3. Pathogenesis of Tissue Injury Mediated by Immune Complexes	469

C. Pathways of Host Sensitization	469
I. Cellular Mechanisms	469
1. Central Reactions	469
2. Recirculation of Immunocompetent Cells	470
II. Pathways of Sensitization to Solid Organ Grafts	472
1. Soluble Antigens	474
2. Macrophage-Processed Antigen	475
3. Peripheral Sensitization	476
4. Passenger Leukocytes	477
D. Hyperacute Rejection	478
I. Pathogenesis	478
II. Pathology of the Hyperacute Rejection	480
1. Kidney	481
a) Course of Events	481
b) Cellular Mechanisms and Mediators Involved in Hyperacute Rejection	482
2. Heart	484
3. Liver	485
4. Lungs	490
5. Pancreas	493
III. Nonimmunologically Caused Primary Graft Failure and Damage	493
1. Pretransplantation Anoxic Lesion	493
2. Mechanical Traumatization	495
3. Morphology of the Pretransplantation Ischemic and Mechanical Damage	496
a) Kidney	499
b) Heart	499
c) Liver	499
d) Lung	500
e) Pancreas	500
E. Accelerated (Delayed Hyperacute) Rejection	500
F. Acute (Intermediate) Rejection	506
I. Pathogenesis	506
1. Cellular Infiltration and Vascular Lesions	508
2. Mechanisms of Acute Cell-Mediated Graft Rejection	518
II. Particular Patterns of Acute Rejection	528
1. Kidney	528
2. Heart	529
3. Liver	531
4. Lung	539
5. Pancreas	545
6. Small Bowel	546
G. Chronic or Late Rejection	548
I. Arterial Obliterative Lesion	548
II. Interstitial Fibrosis, Parenchymal Atrophy and Chronic Cellular Infiltration	550
III. Chronic Glomerulopathy	552
H. Future Prospects of Organ Transplantation	557
I. Current Experience in Organ Transplantation	557
II. Histocompatibility Typing	562
III. Organ Preservation and Storage	563
1. Simple Hypothermic Storage	563
2. Short-Term Preservation	564
3. Intermediate-Term Storage and Long-Term Preservation	565
IV. Artificial Organs	568
V. Modification of the Immune Response	569
1. Immunosuppression	569
2. Immunologic Enhancement	571
3. Immunosuppressive Antibodies	572
4. Immunologic Tolerance	573

5. Specific Immunologic Unresponsiveness	574
6. Attempts to Render the Graft Nonantigenic	574
VI. Xenotransplantation	576
VII. Abbreviations and Definitions	576
References	581

Bone Transplantation in Animals and in Man. LEONHARD SCHWEIBERER and FLORIAN EITEL. With 11 Figures	617
A. Introduction and Historical Review	617
B. Anatomy and Physiology of Intact Bone	618
1. Structural Elements of Bone	618
1.1. Osteoblasts	618
1.2. Osteoclasts	619
1.3. Osteocytes	619
1.4. Collagen	620
1.5. Amorphous Intercellular Substance	620
1.6. Hydroxyapatite	621
2. Transformation of Bone Tissue	621
2.1. Physiologic Transformation	621
2.2. Adaptation of Bone to Mechanical Forces	622
2.3. Pathologic Bone Transformation	623
C. Bone Transplantation	624
1. Blood Supply to Transplanted Bone Tissue	624
2. Osteogenesis in Autografts	625
2.1. Osteogenesis in Transplanted Periosteum	626
2.2. Osteogenesis in Transplanted Compact Bone	628
2.3. Osteogenesis in Transplanted Cancellous Bone	628
2.4. Osteogenesis by Induction	629
3. Immunology of Homologous and Heterologous Bone Transplantation	631
3.1. Bone Homografts	632
3.2. Bone Heterografts	633
4. Transplantation of Pretreated Bone Ground Substance	633
5. Conclusions Drawn From the Results of Experimental Bone Transplantation	639
D. Clinical Aspects of Bone Transplantation	640
1. Cancellous Bone Autografts	641
2. Clinical Scale of Merit of Autografts	641
3. Graft Bed	642
3.1. Stable, Well-Vascularized Bed	642
3.2. Secondarily Stable Bed With Impaired Vascularization (Pseudarthroses and Fresh Fractures)	642
3.3. Continuity Defects of the Long Bones	644
3.4. Grafting into a Septic Milieu	644
E. Conclusion	648
References	648

Radiation-Induced Tolerance. RAINER STORB and C.C. CONGDON. With 5 Figures and 2 Tables	655
A. Introduction and History	655
B. Humoral Immunity	656
I. Primary and Secondary Immune Response	656
II. Time of Irradiation and Antigen Injection	657
III. Radiation Type and Amount	658
IV. Type of Antigen	660

C. Cellular Immunity	660
I. Bone Marrow Grafting	660
1. Irradiation Dose	662
a) Injury	662
α) Hematopoietic	662
β) Gastrointestinal	662
γ) Central Nervous System (CNS)	663
b) Conditioning of Recipients for Hematopoietic Grafting	663
α) The Middlelethal Dose (MLD) Effect	663
β) Rejection of the Marrow Graft and "Reversal"	663
γ) Exposure Rate Effects	664
δ) Conditioning by Irradiation Other Than Total Body (TBI)	664
ζ) Time of Marrow Infusion in Relation to Irradiation	664
2. Histocompatibility Differences Between the Host and Donor	665
3. The Presensitized Recipient	668
4. Successful Hematopoietic Engraftment	669
a) Evidence of Chimerism	669
b) GVHD	670
α) Pathology	670
β) The Prevention and Treatment of GVHD	671
c) Immunologic Reconstitution of Chimeras	673
d) Long-Term Survivors as Examples of Irradiation Induced Immunologic Unresponsiveness: "True Tolerance" or "Enhancement Phenomenon"?	676
e) Clinical Marrow Grafting Studies	680
α) Marrow Grafting in Hematologic Malignancy	681
β) Marrow Grafting in Aplastic Anemia	684
γ) Conclusions and Summary of Outstanding Problems in the Field of Irradiation and Clinical Marrow Grafting	685
II. Other Organ Grafts	686
References	687

Immunosuppression by Antibodies. K. WONIGEIT and R. PICHLMAYR. With 4 Figures 695

A. Introduction	695
B. Concepts of Immunosuppression by Antibodies	695
C. Xenogeneic Antilymphocyte Sera	698
I. General Aspects	698
II. Types of Xenogeneic Antilymphocyte Sera	699
III. Effects on Lymphoid Cells in vitro	701
IV. Effects on the Lymphatic System	702
V. Immunosuppressive Activity of ALS	706
1. Humoral Immunity	706
2. Delayed Hypersensitivity	706
3. Transplantation Immunity	706
4. Autoimmune Phenomena	707
5. Graft-Versus-Host Immunity	707
VI. Cooperative Effects With Other Immunosuppressive Regimens	708
VII. Assays for Immunosuppressive Potency	709
VIII. Mode of Action	710
IX. Side-Effects and Complications	711
1. Toxic Effects	712
2. Hyperergic Reactions	713
3. Infections	713
4. Neoplasms	714
X. Immunosuppression with ALS in Humans	715

D. Passive Enhancement	718
I. General Aspects	718
II. Types of Antibodies Initiating Enhancement	719
III. Prolongation of Allograft Survival by Passive Enhancement	721
IV. Immune Status of Passively Immunized Allograft Recipients	722
V. Mechanisms of Enhancement	723
VI. Side-Effects and Complications	726
VII. Immunologic Enhancement in Humans	727
References	730

Medications and Their Toxicity. EDWARD S. HENDERSON and GERHARD R.F. KRUEGER.

With 23 Figures and 2 Tables	745
A. Introduction	745
B. Pharmacology and Immunopathology	746
I. Adrenocorticosteroids	747
II. Alkylating Agents	749
III. Antimetabolites	751
IV. Vinca Alkaloids	755
V. L-Asparaginase	756
VI. Miscellaneous Agents	757
VII. Antilymphocyte Sera (ALS)	760
C. Toxicology and Adverse Effects	763
I. Adrenocorticosteroids	763
II. Alkylating Agents	765
III. Antimetabolites	770
IV. Vinca Alkaloids	774
V. L-Asparaginase	775
VI. Miscellaneous Agents	777
VII. Antilymphocyte Sera (ALS)	779
D. Special Topics	780
I. Infection	780
II. Carcinogenesis	783
E. Summary	784
References	785

Graft-Versus-Host-Reactions. H.P. HOBICK. With 26 Figures 793

1. Introduction	793
2. Experimental Models	794
2.1. Systemic GVHR	794
2.1.1. Juvenile Forms	795
2.1.1.1. Chorioallantoic Membrane Test	795
2.1.1.2. A→A+B Type	796
2.1.1.3. DA→Fischer+DA-Type	798
2.1.2. Adult Forms	798
2.1.3. Reaction Parameter	799
2.1.3.1. Weight of the Spleen	799
2.1.3.2. Number of Lymphocytes	801
2.1.3.3. Body Weight	801
2.1.3.4. Survival Time	802
2.1.3.5. Phagocytosis Index	804
2.1.3.6. Other Reaction Parameters	805
2.2. Local GVHR	805
2.2.1. The Intrarenal Form	805
2.2.2. The Intracutaneous Form	806
2.2.3. Popliteal Lymph Node Test	806

2.2.4.	The Intra-Ocular Form	807
2.3.	In-Vitro Analogies	808
2.3.1.	The Mixed Lymphocyte Culture	808
2.3.2.	The Spleen Explant Test	809
3.	Clinical Observations	809
3.1.	“Spontaneous” GVHD in Humans	811
3.2.	GVHD After Bone Marrow Transplantation	812
3.2.1.	In Case of Primary Immunodeficiency or Aplastic Anemia	812
3.2.2.	In Leukemias	812
3.2.3.	After Blood Transfusions	813
4.	Histopathology	814
4.1.	Mice	814
4.1.1.	Spleen	814
4.1.2.	Lymph Nodes	815
4.1.3.	Liver	816
4.1.4.	Skin	817
4.1.5.	Bone Marrow	817
4.1.6.	Other Tissues	817
4.2.	Rats	818
4.2.1.	Spleen	818
4.2.2.	Lymph Nodes	819
4.2.3.	Liver	819
4.2.4.	Skin	820
4.2.5.	Bone Marrow	821
4.2.6.	Other Tissue	824
4.3.	Chickens	825
4.4.	Other Animals	826
4.5.	Humans	827
4.5.1.	Spleen	827
4.5.2.	Lymph Nodes	828
4.5.3.	Liver	829
4.5.4.	Skin	830
4.5.5.	Gastrointestinal Tract	833
4.5.6.	Bone Marrow	834
4.5.7.	Remaining Tissue	834
5.	Hematology	835
5.1.	Mice	835
5.2.	Rats	836
5.3.	Other Species of Animals	836
5.4.	Humans	836
6.	Causal Pathogenesis	837
6.1.	Immunologic Factors	837
6.2.	Unspecific Factors	837
7.	Formal Pathogenesis	838
7.1.	Trigger Antigens	838
7.2.	Immunocompetent Lymphocytes	839
7.3.	Behaviour of Donor Lymphocytes	839
7.3.1.	Nidation	839
7.3.2.	Proliferation	840
7.3.3.	Cellular Interactions	840
7.4.	Behaviour of Host Cells	841
7.4.1.	Damages	841
7.4.2.	Reactive Hyperplasia and Allogeneic Effect	842
7.4.3.	Immune Suppression	843
7.5.	Mechanisms of Immune Regulations	844
8.	Therapeutic Influence	846
8.1.	Results of Experiments with Animals	846

8.1.1.	Treatment of Donor Animals	847
8.1.2.	Treatment of Donor Cells	848
8.1.3.	Treatment of Host Animals	849
8.2.	Clinical Results	852
9.	Late Complications	853
9.1.	Glomerulonephritis	853
9.2.	Other Forms of Allogeneic Diseases	853
9.3.	Malignant Tumors	854
10.	Prospects	855
References		857
Author Index		877
Subject Index		995